Skip to main
MYGN
MYGN logo

Myriad Genetics (MYGN) Stock Forecast & Price Target

Myriad Genetics (MYGN) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 18%
Hold 55%
Sell 9%
Strong Sell 0%

Bulls say

Myriad Genetics Inc. is poised for growth, with expectations of a meaningful strengthening of its oncology portfolio over the next 12-18 months, including several key product launches such as Precise MRD and enhancements to MyRisk. The financial outlook indicates a projected total revenue growth of approximately 6% year-over-year by 2026, driven largely by a 10% growth in prenatal testing and mid-single-digit increases across hereditary cancer testing, tumor profiling, and pharmacogenomics. Despite some near-term challenges, particularly in the integration of electronic medical records for hereditary testing, the anticipated increases in test volumes across various segments support a positive long-term view on Myriad's stock.

Bears say

The excerpts indicate a significant downgrade of Myriad Genetics's stock to Sector Perform, along with a lower price target set at $6. This repeated downgrade suggests a consensus among analysts regarding concerns over the company's financial performance and future growth potential. The lack of upward momentum in the stock's valuation highlights underlying challenges that may affect investor confidence in Myriad Genetics's market position and profitability.

Myriad Genetics (MYGN) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 18% recommend Buy, 55% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myriad Genetics (MYGN) Forecast

Analysts have given Myriad Genetics (MYGN) a Hold based on their latest research and market trends.

According to 11 analysts, Myriad Genetics (MYGN) has a Hold consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myriad Genetics (MYGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.